Clinical Trials Navigator

Clinical Trials Navigator — Lesson 4 Decision Assistant

Clinical Trials Navigator

Lesson 4 — Phase I • Phase II • Phase III • Phase IV — structured, interactive planning

How to use this tool

  1. Phase I: Configure SAD/MAD, escalation model, DLT window, PK/PD → get MTD/RP2D plan & safety governance.
  2. Phase II: Randomization, blinding, dose-ranging, endpoints → get efficacy-focused trial skeleton.
  3. Phase III: Multicenter confirmatory design, comparators, endpoints, regulatory view.
  4. Phase IV: RWE/registries, long-term safety, signal detection, labeling updates.
  5. Scenarios: Load the worked examples to see complete outputs.
  6. Outputs: Copy/print/export JSON for protocol notes.
Note: Educational planning aid — align with regulations, ICH-GCP, IRB/IEC, DSMB, and institutional SOPs.

Core ideas

Safety first (Ph I)Signal & dose (Ph II) Confirmation (Ph III)RWE & PV (Ph IV)
SAD/MAD3+3 / BOIN / CRM Randomization & BlindingDSMB

Phase I Planner (Lesson 4.1)

Design & Safety Governance

Fill inputs and click Build Phase I Plan.
What Phase I establishes
  • Safety & tolerability, DLTs, MTD and/or RP2D
  • PK (ADME) & PD signals
  • Framework for later-phase dosing

Phase II Planner (Lesson 4.2)

Efficacy-Focused Trial Skeleton

Set inputs and click Build Phase II Plan.
Tips
  • Pre-specify dose-ranging and analysis (e.g., MMRM/ANCOVA)
  • Multiplicity control if multiple doses/endpoints
  • DSMB advisable for higher-risk programs

Phase III Planner (Lesson 4.3)

Confirmatory Trial & Regulatory View

Set inputs and click Build Phase III Plan.
Regulatory lens
  • Pre-specified estimands & SAP; multiplicity control
  • Global site quality, central randomization/blinded adjudication
  • Datasets/analysis to support NDA/MAA

Phase IV Planner (Lesson 4.4)

RWE, Pharmacovigilance & Labeling

Select inputs then click Build Phase IV Plan.
Signal detection
  • Disproportionality, SCCS, new-user active comparators
  • Rapid AE triage & aggregate periodic review

Load Example Scenarios

Phase I — “Cardiopril” (SAD/MAD)

60 HV; SAD 5–20 mg; MAD 7 days; DLT 28d; PK rich; DSMB.

Phase II — “Glucostop”

T2D; 200 pts; 3-arm 1:1:1; HbA1c at 12w; placebo-controlled; DB.

Phase III — “Diabetex”

1,500 pts; DB; placebo; 24w; HbA1c primary; multicenter.

Phase IV — “Hypotensix”

Registry/EHR; 10k; 5y; rare AEs + BP control; labeling updates.

Outputs

Consolidated Plan

Build any section to populate this area.

Summary Tables

Phase I — Purpose
AspectDescriptionExample
Primary goalsSafety, tolerability, PK/PD; find MTD/RP2DOncology agent MTD and AEs
Phase I — Design
AspectDescriptionExample
Participants20–100 HV or patients (if higher risk)50 HV antihypertensive
Study designSAD/MAD; dose-escalation to MTDSAD groups increasing dose
EndpointsSafety/AE/SAE; PK/PDHalf-life to set dosing freq
Phase II — Purpose & Design
AspectDescriptionExample
PurposeEfficacy signal & continued safetyAsthma attack reduction
Participants100–300 patients with condition200 RA patients
DesignRandomized, controlled; dose-rangingDB antidepressant vs placebo
EndpointsPrimary efficacy; secondary safetyΔ HbA1c; hypoglycemia AEs
Phase III — Confirmatory Design
AspectDescriptionExample
ParticipantsHundreds–thousands; representative1,000 HTN patients
DesignRandomized, DB, often placebo/activeDB antidepressant Phase III
EndpointsPrimary clinical efficacy; safety↓ migraine days; AE tracking
Phase IV — RWE & PV
AspectDetailsExample
PurposeLong-term effectiveness & rare AEsBP med CV outcomes monitor
DesignObservational registries; additional RCTEHR cohort on new statin
EndpointsPrimary safety; secondary effectiveness/PROsLiver tox incidence; QoL
RegulatoryPost-marketing commitments; labeling updatesBoxed warning update if needed
Phase II — Teaching & Assessment
MethodDescription
LectureSlides on design/methods with visuals
Interactive DiscussionEthics, challenges, real cases
Case StudyDesign, endpoints, outcomes
Q&AClarify concepts
ReadingArticles/chapters on Phase II
AssessmentDescription
QuizGoals, randomization, endpoints, consent
PracticalDesign a Phase II with endpoints & safety